AA
ZBIO

ALPS Advisors’s Zenas BioPharma ZBIO Stock Holding History

ALPS Advisors’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
63,675
+19,981
+46% +$397K 0.01% 586
2026
Q1 		$854K Sell
43,694
-383
-0.9% -$8.6K ﹤0.01% 604
2025
Q4 		$1.6M Buy
44,077
+24,035
+120% +$790K 0.01% 437
2025
Q3 		$445K Sell
20,042
-2,511
-11% -$40.9K ﹤0.01% 819
2025
Q2 		$219K Sell
22,553
-5,579
-20% -$54.3K ﹤0.01% 1003
2025
Q1 		$222K Sell
28,132
-5,658
-17% -$44.3K ﹤0.01% 956
2024
Q4 		$277K Buy
+33,790
New +$527K ﹤0.01% 935

Other funds holding ZBIO

IGAM
iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

ALPS Advisors's ZBIO Position: Q2 2026 in Review

ALPS Advisors increased its Zenas BioPharma (ZBIO) stake by 46% in Q2 2026, buying an estimated $397K and bringing the position to 63,675 shares worth $1.62M. The position accounts for 0.01% of the portfolio, ranked #586.

ALPS Advisors first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. 17 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • ALPS Advisors held 63,675 shares of Zenas BioPharma worth $1.62M as of Q2 2026.
  • ALPS Advisors bought 19,981 Zenas BioPharma shares in Q2 2026, an estimated $397K.
  • Zenas BioPharma made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #586 holding.
  • ALPS Advisors first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
  • 17 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.